undamentalytics Newsletter
Sign in

Mesa Laboratories Inc (MLAB) stock

Add to watchlist

Add holding +

NASDAQ: MLAB Nasdaq Life Sciences Tools & Services Next results ~November 9, 2026

B Fundamentals grade

Mesa Laboratories Inc is a US-listed company in the life sciences tools & services industry. Its financial year ends in March.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$120

Cash-flow model

Base case. Range ~$87–$160 across our lower- and higher-growth cases (-1.3%–8.7% a year).

Price vs value

Modestly overvalued

The price is inside our value range, 3% above our base value.

Price used: $121.97, November 2, 2026

Mesa Laboratories Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 4 selling5 purchases and 7 sales by directors and officers, last 12 monthsInsider trades
  • Funds92 adding, 56 cuttingOf 37 active managers that changed their stake, 21 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Mesa Laboratories files

Where Mesa Laboratories stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $250m, up 3.0% on a year earlier, about the same pace as a quarter earlier. Free-cash-flow margin rose to 21.2% from 13.9% a year earlier. Operating margin widened to 9.0% from 5.7%. The diluted share count is up 3.0% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 3 of our 6 financial-health checks. Our cash-flow model value is $115 a share, against a share price of $134. At that price, our model says the market is pricing in about 6.3% a year of cash-flow growth for five years, close to the 6.3% a year revenue growth it has delivered.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Mesa Laboratories Inc's trailing-twelve-month revenue grew 3.0% year on year, with a free-cash-flow margin of 21.2%. Where it stands out: free-cash-flow margin of 21.2% ranks 7 of 54 life sciences tools & services companies we cover.

Our discounted-cash-flow model values the business at ~$120 per share in the base case (~$87–$160 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Gross margin expanding: TTM gross margin reached 64.2%, up 2.1pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 3.3 points on a year ago.
  • Strong cash generation. 21.2% of revenue turned into free cash flow, against a median of -1.3% for life sciences tools & services companies we cover.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Share dilution. Diluted shares rose 3.0% in a year.
  • High earnings multiple. The shares trade at 143 times the last 12 months' earnings, so expectations are demanding.
  • Volatile shares. Over the past year the shares showed annualised volatility of 53% and a beta of 1.3 against the S&P 500.

Latest results: FY2027 Q1

Filed August 10, 2026
Earnings per share
$1.30 against an average estimate of $2.55: missed by 49.1%
Revenue
$60m, up 1.0% on a year earlier
Share reaction
+8.4% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Next report
November 9, 2026; average EPS estimate $2.24

Mesa Laboratories' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.6%
  • 1 week-6.1%
  • 1 month-8.0%
  • This year+56.1%
  • 1 year+70.8%
  • 5 years-59.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$250M
Operating margin
9.0%
Net margin
1.9%
EPS (TTM, diluted)
$0.85

Growth

Revenue growth
+3.0%
Change in growth rate
−0.3 pts
Share count change
+3.0%

Cash

Free cash flow (TTM)
$52.9M
FCF margin
21.2%
Stock pay % of revenue
6.5%

Earnings

Last results
August 10, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Restructuring
  2. Shareholder vote
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Mesa Laboratories Inc valuation models and calculator

What the price is pricing in

The share price implies about 4.8% a year of cash-flow growth for five years.That is close to the 6.3% a year revenue growth Mesa Laboratories has delivered.

  • Priced in4.8%
  • Last 12 months3.0%
  • 3 years a year4.4%
  • 5 years a year6.3%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($125.61, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Hold12-month view
12-month price target
~$120
Price used
$125.61close November 3, 2026
Implied change
▼ 6%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Mesa Laboratories Inc's free cash flow after stock-based pay with after-tax interest added back ($37.9M, FY2027 Q1 TTM), growing 3.6% and 4.1% in the next two years (forecasts, guidance and its record), then back to 3.7% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$87–~$160 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Mesa Laboratories Inc's free cash flow after stock-based pay ( $37.9M, FY2027 Q1 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Mesa Laboratories Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.03 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$120 ~$87–$160 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$29 ~$27–$32 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$89 ~$29–$120 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Mesa Laboratories Inc with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −26%
  • Revenue growth 5 points higher ▲ +34%
  • Free-cash-flow margin 1 point lower ▼ −4%
  • Last year's free-cash-flow margin change, if it persists ▲ +44%
  • Discount rate 1 point higher ▼ −15%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $92$126$173$234$314$417
8.5% $69$94$127$171$228$301
10% $55$74$100$134$177$232

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026Now
Share price$92.06$117.89$143.27$223.20$219.51$237.00$248.66$171.07$108.04$117.44$88.17$121.97
Market value$346m$453m$540m$900m$959m$1.2bn$1.3bn$917m$582m$637m$491m$685m
+ Net debt (− = net cash)$40m$49m$41m$13m$59m−$118m$120m$137m$143m$137m$41m$35m
Enterprise value$385m$503m$581m$913m$1.0bn$1.1bn$1.4bn$1.1bn$725m$774m$531m$720m
Multiples
Price / sales 4.1x4.8x5.6x8.7x8.2x9.1x7.2x4.2x2.7x2.6x2.0x2.7x
Price / earnings 31.0x40.5x—120.3xn/mn/mn/mn/m——73.1x142.7x
Price / free cash flow ——23.6x30.7x37.6x34.6x38.1x39.1x14.0x15.0x12.4x13.0x
EV / EBITDA 16.4x20.1x49.8x47.5x48.7x36.5x48.6x28.4x—35.6x22.4x26.1x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

44 /100

Weak moat

How hard Mesa Laboratories's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median 0.1% of total assets over 10 years.

  • Pricing power 19 / 20

    Gross margin has been a median 60.2%, moving by 2.6 percentage points (standard deviation) across 10 years.

  • Durability 0 / 20

    Operating margin has been a median 5.4%; its worst year was -118.8%.

  • Cash conversion 19 / 20

    Free cash flow was positive in 7 of 7 years, at a median 18.7% of revenue.

  • Discipline 10 / 20

    The diluted share count rose 6.3% over five years; stock-based pay has been a median 5.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (49 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $62m and EPS of $2.24 (range $2.24 to $2.24) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $9.95 +19% $254m +2%
Next $10.27 +3% $271m +7%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +84.6% on 90 days ago. In the last 30 days, 0 analysts raised Mesa Laboratories Inc's forecast and 1 cut it.

Consensus EPS forecast Mesa Laboratories Inc, last 90 days
$4.00 $6.00 $8.00 $10.00 $12.00 $14.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $5.39 Current fiscal year, 60 days ago: $11.62 Current fiscal year, 30 days ago: $11.62 Current fiscal year, 7 days ago: $11.62 Current fiscal year, Now: $9.95 $9.95 Next fiscal year, 60 days ago: $12.27 Next fiscal year, 30 days ago: $12.27 Next fiscal year, 7 days ago: $12.27 Next fiscal year, Now: $10.27 $10.27

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $5.39$12.27
60 days ago $11.62$12.27
30 days ago $11.62$12.27
7 days ago $11.62$10.27
Now $9.95$0.00

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $2.55 $1.30 −49.1%
Mar 2026 $1.39 $1.83 +31.5%
Dec 2025 $1.47 $1.76 +19.9%
Sept 2025 $1.56 $2.11 +35.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 10, 2026

No numeric guidance in Mesa Laboratories Inc's latest earnings release (filed August 10, 2026). Some companies give their outlook only on the earnings call.

How our valuation uses these forecasts

Our cash-flow model grows Mesa Laboratories Inc's revenue by +3.6% next year and +4.1% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+3.5%, weight 45%) and the company's own record (+3.7%, weight 55%) . How the weights are set.

Analyst recommendations

2 analysts, Oct 2026
Buy150%
Hold150%
Sell00%

Monthly trend

  1. Oct 2026112
  2. Sep 2026123
  3. Aug 2026123

Counts of recommendations published by analysts covering Mesa Laboratories Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.2%
of tradable shares
Days to cover
3.34
at average volume
Short interest, 1 month
−3%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
5.6%
of shares
Employees
717
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +70.8%

$71.43 on October 31, 2025 to $121.97

ThenNowEffect
Revenue (last 12 months) $242m $250m +3.0%
P/S multiple 1.6x 2.7x +70.7%
Share count 5m 6m −2.9%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +33.3%

$91.48 on November 3, 2023 to $121.97

ThenNowEffect
Revenue (last 12 months) $219m $250m +13.9%
Net margin 0.8% 1.9% +131.7%
P/E multiple n/m 142.7x −47.3%
Share count 5m 6m −4.1%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
MLAB+15%−49%−37%+27%−40%+56%
Industry peers (median)+4%−53%−3%−15%−2%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
MLAB58%17%33%50%33%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
MLAB−21%−64%−58%−30%−63%−24%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 82% from December 27, 2021 to August 5, 2025. Getting back needed a 469% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$70.15 – $142.23
From 52-week high
−14.2%
vs 50-day average
−5.0%
vs 200-day average
+17.1%
Volatility (1 year)
53%
Beta vs S&P 500
1.28

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±7.5%
After a week
7 up, 5 down
typical move ±8.8%
After a month
8 up, 4 down
typical move ±9.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 +8.4% −0.3% +4.9% +20.9%
May 27, 2026 −2.9% +0.5% −1.5% −3.4%
February 3, 2026 +13.7% −1.3% +14.2% +9.0%
November 6, 2025 +2.4% −1.0% +2.2% +5.3%
August 5, 2025 −18.9% +0.3% −17.3% −15.7%
May 28, 2025 −7.6% −0.2% −10.7% −12.7%
February 4, 2025 +3.7% +1.1% +12.4% +3.3%
November 7, 2024 −11.4% +1.2% −22.0% −2.2%
August 5, 2024 +5.8% −2.0% +9.6% +13.5%
June 5, 2024 +13.3% +1.2% +0.7% +0.4%
February 5, 2024 +2.0% −0.1% +1.4% +19.1%
November 6, 2023 +0.1% +0.5% −9.3% +2.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Mesa Laboratories Inc in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Mesa Laboratories Inc
$210M $220M $230M $240M $250M FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue (TTM), FY24 Q2: $213.7M Revenue (TTM), FY24 Q3: $212.9M Revenue (TTM), FY24 Q4: $216.2M Revenue (TTM), FY25 Q1: $223.7M Revenue (TTM), FY25 Q2: $228.4M Revenue (TTM), FY25 Q3: $237.7M Revenue (TTM), FY25 Q4: $241M Revenue (TTM), FY26 Q1: $242.4M Revenue (TTM), FY26 Q2: $245.3M Revenue (TTM), FY26 Q3: $247.5M Revenue (TTM), FY26 Q4: $249.1M Revenue (TTM), FY27 Q1: $249.7M $249.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $213.7M
FY24 Q3 $212.9M
FY24 Q4 $216.2M
FY25 Q1 $223.7M
FY25 Q2 $228.4M
FY25 Q3 $237.7M
FY25 Q4 $241M
FY26 Q1 $242.4M
FY26 Q2 $245.3M
FY26 Q3 $247.5M
FY26 Q4 $249.1M
FY27 Q1 $249.7M
Revenue growth, TTM YoY Mesa Laboratories Inc
-5% 0% 5% 10% 15% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue growth, TTM YoY, FY24 Q2: -4.1% Revenue growth, TTM YoY, FY24 Q3: -4.3% Revenue growth, TTM YoY, FY24 Q4: -1.3% Revenue growth, TTM YoY, FY25 Q1: 2.0% Revenue growth, TTM YoY, FY25 Q2: 6.9% Revenue growth, TTM YoY, FY25 Q3: 11.7% Revenue growth, TTM YoY, FY25 Q4: 11.5% Revenue growth, TTM YoY, FY26 Q1: 8.3% Revenue growth, TTM YoY, FY26 Q2: 7.4% Revenue growth, TTM YoY, FY26 Q3: 4.1% Revenue growth, TTM YoY, FY26 Q4: 3.4% Revenue growth, TTM YoY, FY27 Q1: 3.0% 3.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q2 -4.1%
FY24 Q3 -4.3%
FY24 Q4 -1.3%
FY25 Q1 2.0%
FY25 Q2 6.9%
FY25 Q3 11.7%
FY25 Q4 11.5%
FY26 Q1 8.3%
FY26 Q2 7.4%
FY26 Q3 4.1%
FY26 Q4 3.4%
FY27 Q1 3.0%
Operating margin (TTM) Mesa Laboratories Inc
-150% -100% -50% 0% 50% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Operating margin (TTM), FY24 Q2: 1.5% Operating margin (TTM), FY24 Q3: -0.1% Operating margin (TTM), FY24 Q4: -125.9% Operating margin (TTM), FY25 Q1: -118.8% Operating margin (TTM), FY25 Q2: -114.8% Operating margin (TTM), FY25 Q3: -107.9% Operating margin (TTM), FY25 Q4: 6.8% Operating margin (TTM), FY26 Q1: 5.7% Operating margin (TTM), FY26 Q2: 6.1% Operating margin (TTM), FY26 Q3: 7.0% Operating margin (TTM), FY26 Q4: 7.4% Operating margin (TTM), FY27 Q1: 9.0% 9.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 1.5%
FY24 Q3 -0.1%
FY24 Q4 -125.9%
FY25 Q1 -118.8%
FY25 Q2 -114.8%
FY25 Q3 -107.9%
FY25 Q4 6.8%
FY26 Q1 5.7%
FY26 Q2 6.1%
FY26 Q3 7.0%
FY26 Q4 7.4%
FY27 Q1 9.0%
FCF margin (TTM) Mesa Laboratories Inc
12% 14% 16% 18% 20% 22% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 FCF margin (TTM), FY24 Q2: 17.0% FCF margin (TTM), FY24 Q3: 19.1% FCF margin (TTM), FY24 Q4: 19.2% FCF margin (TTM), FY25 Q1: 18.7% FCF margin (TTM), FY25 Q2: 15.8% FCF margin (TTM), FY25 Q3: 18.1% FCF margin (TTM), FY25 Q4: 17.7% FCF margin (TTM), FY26 Q1: 13.9% FCF margin (TTM), FY26 Q2: 15.2% FCF margin (TTM), FY26 Q3: 15.3% FCF margin (TTM), FY26 Q4: 15.9% FCF margin (TTM), FY27 Q1: 21.2% 21.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 17.0%
FY24 Q3 19.1%
FY24 Q4 19.2%
FY25 Q1 18.7%
FY25 Q2 15.8%
FY25 Q3 18.1%
FY25 Q4 17.7%
FY26 Q1 13.9%
FY26 Q2 15.2%
FY26 Q3 15.3%
FY26 Q4 15.9%
FY27 Q1 21.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2026, from the 10-K

Each dollar Mesa Laboratories took in during FY2026, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $249M
  2. Cost of revenue $90.9M · 36.5%
  3. Gross profit $158M · 63.5%
  4. Research and development $20.3M · 8.2%
  5. Selling, general and admin $78.7M · 31.6%
  6. Other operating costs $40.8M · 16.4%
  7. Operating income $18.5M · 7.4%
  8. Income tax $5.3M · 2.1%
  9. Interest and other $6.5M · 2.6%
  10. Net income $6.7M · 2.7%

Shares of revenue. Source: Mesa Laboratories's 10-K for FY2026, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Mar 2011 2012 Mar 2012 2013 Mar 2013 2014 Mar 2014 2015 Mar 2015 2016 Mar 2016 2017 Mar 2017 2018 Mar 2018 2019 Mar 2019 2020 Mar 2020 2021 Mar 2021 2022 Mar 2022 2023 Mar 2023 2024 Mar 2024 2025 Mar 2025 2026 Mar 2026 LTM Jun 2026
Income
Revenue 34 40 46 53 71 85 94 96 103 118 134 184 219 216 241 249 250
Gross profit 20 24 29 32 43 51 53 55 61 65 87 109 134 133 151 158 160
EBITDA 12 15 17 16 22 23 25 12 19 21 30 30 37 −268 22 24 28
Operating income 10 12 13 12 16 16 16 2 10 8 12 5 3 −272 16 19 22
Net income 6 8 8 9 10 11 11 −3 7 2 3 2 1 −254 −2 7 5
Diluted EPS $1.86 $2.29 $2.35 $2.49 $2.63 $2.97 $2.91 −$0.79 $1.86 $0.41 $0.64 $0.35 $0.17 −$47.20 −$0.36 $1.21 $0.85
Growth (year on year)
Revenue — +15.7% +17.2% +13.5% +35.3% +18.7% +10.6% +2.7% +7.2% +14.1% +13.8% +37.6% +18.8% −1.3% +11.5% +3.4% +3.0%
EBITDA — +25.5% +12.6% −5.5% +37.7% +9.2% +6.6% −53.5% +64.8% +8.9% +43.5% −0.8% +24.8% −821.1% — +9.4% +43.6%
Operating income — +26.5% +5.0% −10.1% +34.6% +2.9% −0.1% −86.6% +348.1% −19.0% +56.0% −62.0% −29.4% — — +13.3% +62.6%
Net income — +28.1% +6.7% +6.5% +6.5% +16.6% +0.1% −126.5% — −76.2% — −42.9% — — — — —
Diluted EPS — +23.1% +2.6% +6.0% +5.6% +12.9% −2.0% −127.1% — −78.0% — −45.3% — — — — —
Margins
Gross margin 57.2% 59.3% 62.2% 60.1% 60.8% 60.7% 56.8% 56.8% 59.1% 55.5% 65.0% 59.2% 61.0% 61.6% 62.6% 63.5% 64.2%
EBITDA margin 34.2% 37.1% 35.6% 29.6% 30.2% 27.8% 26.7% 12.1% 18.6% 17.8% 22.4% 16.1% 17.0% −123.9% 9.0% 9.5% 11.0%
Operating margin 28.8% 31.5% 28.2% 22.4% 22.2% 19.3% 17.4% 2.3% 9.5% 6.7% 9.2% 2.6% 1.5% −125.9% 6.8% 7.4% 9.0%
Net margin 18.1% 20.0% 18.2% 17.1% 13.4% 13.2% 11.9% −3.1% 7.3% 1.5% 2.4% 1.0% 0.4% −117.6% −0.8% 2.7% 1.9%
Free-cash-flow margin — — — — — — — 23.8% 28.4% 21.7% 26.2% 18.9% 10.7% 19.2% 17.7% 15.9% 21.2%
Cash flow
Cash from operations 9 12 11 12 11 17 17 26 31 27 37 39 28 44 47 43 56
Capital spending — — — — — — — 3 1 1 2 4 5 3 4 3 3
Free cash flow — — — — — — — 23 29 25 35 35 23 42 43 40 53
Stock-based pay 0 0 1 1 1 1 1 2 4 6 9 11 13 12 13 18 16
Free cash flow after stock pay — — — — — — — 21 25 20 26 23 11 30 29 22 37
Balance sheet
Cash 4 7 4 6 2 6 6 5 10 81 264 49 33 28 27 27 31
Total debt 11 2 4 17 26 45 55 46 23 140 146 169 170 171 164 68 66
Net debt (negative = net cash) 7 −5 −0 11 24 40 49 41 13 59 −118 120 137 143 137 41 35
Diluted shares 3m 3m 4m 4m 4m 4m 4m 4m 4m 4m 5m 5m 5m 5m 5m 6m 6m
Returned to shareholders
Dividends 1 2 2 2 2 2 2 2 2 3 3 3 3 3 3 4 4
Buybacks 0 1 0 0 — — — — — — — — — — — — —
Total returned 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 4 4

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $419m
Short-term assets $103mLonger-term assets $316m
What it owes, and who funded it · $419m
Short-term liabilities $57mLonger-term liabilities $173mShareholders' equity $189m
  • Short-term assets cover short-term liabilities $103m of assets due within a year against $57m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $103m short-term assets against $173m of longer-dated liabilities.
  • More cash than debt $31m of cash against $66m of debt.
  • Debt below 40% of shareholders' equity Debt is 35% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $56m of operating cash flow against $66m of debt.
  • Operating profit covers interest at least five times over Operating income of $22m against $11m of interest.

From Mesa Laboratories Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Dividends (TTM)
$3.5M
Diluted share count
+3.0%
year over year
Total shareholder yield
0.5%
dividends 0.5% + buybacks 0.0% of market value
Dividend payout ratio
74%
of net income paid out
R&D spending
8.0%
of revenue
Days sales outstanding
50 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated MLAB SDGR MRVI CTKB FLGT CYRX Median
Revenue, last 12 months $250m $259m $209m $207m $324m $186m $229m
Revenue growth, last 12 months 3.0% 8.9% −5.0% 5.4% 6.8% 12.1% 6.9%
Revenue growth, 3-year average 4.4% 10.2% −27.3% 5.6% 1.8% −8.2% 2.9%
Revenue growth, latest quarter 1.0% 7.5% 8.5% 5.6% 4.4% 7.7% 8.5%
Gross margin 64.2% 56.9% 34.9% 53.2% 35.6% 47.1% 51.9%
Operating margin 9.0% −59.2% −56.1% −21.6% −37.7% −21.2% −14.3%
Operating margin, 3-year average −34.7% −81.0% −73.7% −16.1% −42.5% −60.1% −22.4%
Net margin 1.9% −21.0% −37.1% −39.0% −26.0% −20.1% −16.1%
Cash from operations / revenue 22.3% −49.0% −12.1% −2.9% −25.8% 4.3% 1.3%
Free-cash-flow margin 21.2% −50.3% −17.2% −5.9% −32.0% −10.8% −2.2%
Free-cash-flow margin, 3-year average 17.9% −45.4% −14.3% 1.7% −15.9% −22.6% 0.6%
Stock pay / revenue 6.5% 14.9% 14.3% 10.3% 11.6% 5.2% 4.4%
Change in share count 3.0% 1.7% 2.3% −0.3% −1.5% 0.6% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 3.0% 6.9% 37 of 54
Change in growth rate Growth -0.3pp +0.4pp 32 of 54
Gross margin Profitability 64.2% 52.0% 10 of 45
Operating margin Profitability 9.0% -14.3% 10 of 52
Net margin Profitability 1.9% -12.2% 16 of 54
Free-cash-flow margin Cash generation 21.2% -1.3% 7 of 54
Stock pay as % of revenue Cash generation 6.5% 4.4% 30 of 53
Long-term debt as % of assets Balance sheet 15.8% 26.3% 11 of 35
Change in share count Balance sheet 3.0% 1.0% 32 of 46
Days sales outstanding Balance sheet 50 days 62 days 15 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to March 31, 2026
Segments
Line of business Revenue Share YoY
Sterilization and Disinfection Control $102M 40.8% ▲ 8.7%
Calibration Solutions $53.6M 21.5% ▲ 3.5%
Biopharmaceutical Development $48.6M 19.5% ▼ 0.2%
Clinical Genomics $45.4M 18.2% ▼ 3.6%
Products and services
Line of business Revenue Share YoY
Products $203M 81.6% ▲ 2.5%
Services $45.7M 18.4% ▲ 7.4%
Geography
Region Revenue Share YoY
United States $117M 46.9% ▲ 0.2%
Other $112M 44.9% ▲ 12.9%
China $20.4M 8.2% ▼ 19.2%

From Mesa Laboratories Inc's 10-K filed June 3, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$498M
Institutions reporting
158
Shares held vs prior quarter
▲ 4.3%
Positions opened / closed
19 / 18

Top buyers and sellers, Q2 2026: 92 institutions bought and 56 sold ; the biggest buyer was Jacobs Levy Equity Management, Inc (+86K shares) and the biggest seller Select Equity Group, L.P (−236K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Long Path Partners LP $47.5M 477K 9.5% ▲ 17.6%
Blackrock, Inc. $43.9M 441K 8.8% ▲ 11.9%
Boston Partners $26.4M 265K 5.3% ▼ 1.3%
Vanguard Capital Management LLC $23.6M 237K 4.7% ▲ 2.1%
AQR Capital Management LLC $20.3M 204K 4.1% ▲ 19.5%
Ranger Investment Management, L.P. $17.3M 174K 3.5% ▼ 14.3%
Morgan Stanley $15.6M 157K 3.1% ▼ 3.2%
Diamond Hill Capital Management, LLC (Investment Advisor) $15.5M 156K 3.1% ▲ 0.3%
Raymond James Financial Inc $14.9M 150K 3.0% ▲ 22.0%
Dimensional Fund Advisors LP $14.8M 148K 3.0% ▲ 19.1%
Geode Capital Management, LLC $13.9M 140K 2.8% ▲ 9.1%
Kennedy Capital Management LLC $13.8M 138K 2.8% ▼ 2.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Mesa Laboratories Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $1.4M 5 trades by 4 insiders, last 12 months Insider sales History → $1.6M 7 trades by 4 insiders · 32% under pre-set plans
Net ▼ $215,725 net selling
Insider Date Trade Shares Price Value
Tripeny R Tony Director August 13, 2026 Buy 900 $113.69 $102,321
Kadia Siddhartha President and CEO August 13, 2026 Buy 7,093 $112.80 $800,090
Sullivan John James Director August 13, 2026 Sell 7,093 $112.80 $800,090
Sakys John CFO June 22, 2026 Sell pre-set plan 2,827 $89.50 $253,016
Archbold Brian David SVP Operations June 22, 2026 Sell 2,516 $89.50 $225,182
Crennen Lyndsey Elizabeth CAO June 22, 2026 Sell 442 $89.50 $39,559
Sakys John CFO June 16, 2026 Sell pre-set plan 1,223 $101.27 $123,853
Crennen Lyndsey Elizabeth CAO June 16, 2026 Sell pre-set plan 118 $101.27 $11,950
Archbold Brian David SVP Operations June 16, 2026 Sell pre-set plan 1,151 $101.27 $116,562
Tripeny R Tony Director March 10, 2026 Buy 1,315 $76.00 $99,940
Capone Mark Christopher Director March 10, 2026 Buy 1,301 $76.35 $99,331
Ladiwala Shiraz Shabanali Director March 10, 2026 Buy 3,500 $72.23 $252,805

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 10, 2026
  • May 27, 2026
  • February 3, 2026
  • November 6, 2025
  • August 5, 2025
  • May 28, 2025

Recent SEC filings

Data status

When each part of this page on Mesa Laboratories Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Mesa Laboratories Inc in brief

What does Mesa Laboratories Inc do?
Mesa Laboratories Inc is a US-listed company in the life sciences tools & services industry. Its financial year ends in March.
What is Mesa Laboratories Inc's stock ticker?
Mesa Laboratories Inc trades under the ticker MLAB on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Mesa Laboratories Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Mesa Laboratories Inc reported revenue of $250M, 3.0% higher than a year earlier, according to its SEC filings.
What is Mesa Laboratories Inc's free cash flow?
Mesa Laboratories Inc's free-cash-flow margin is 21.2% of revenue over the trailing twelve months, ranking 7 of the 54 life sciences tools & services companies we cover.
What is Mesa Laboratories Inc's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Mesa Laboratories Inc's free cash flow after stock-based pay gives ~$120 per share in the base case, and ~$87–$160 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Mesa Laboratories Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Long Path Partners LP, Blackrock, Inc. and Boston Partners. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Mesa Laboratories Inc's market cap?
On November 2, 2026, Mesa Laboratories Inc's market capitalisation was about $685M, with a price-to-earnings ratio of 142.7 and net debt of $35.4M. Market figures come from third-party market data and may be delayed.
Does Mesa Laboratories Inc pay a dividend?
Yes: Mesa Laboratories Inc paid $3.5M in dividends over the trailing twelve months, a dividend yield of 0.52% and a payout ratio of 73.6%.
How much debt does Mesa Laboratories Inc have?
Mesa Laboratories Inc's debt-to-equity ratio is 35.0%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Mesa Laboratories Inc's competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Mesa Laboratories Inc are Schrodinger, Inc., Maravai Lifesciences Holdings, Inc., Cytek Biosciences, Inc., Fulgent Genetics, Inc. and Cryoport, Inc. The side-by-side comparison below sets their revenue, margins and growth against Mesa Laboratories Inc's.
Are insiders buying or selling Mesa Laboratories Inc stock?
Over the last 12 months, Mesa Laboratories Inc's directors and officers reported 5 open-market purchases and 7 sales on Form 4. The insider trading page charts every trade.
When is Mesa Laboratories Inc's next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Mesa Laboratories Inc announces its own schedule.